Table 1

Patient characteristics at baseline (N=13 991)

Monoclonal anti-TNF antibodies
n=3242 (23.17%)
Soluble TNF receptor fusion protein
n=2513 (17.96%)
T cell costimulation modulator
n=817 (5.84%)
B cell targeted therapies
n=1431 (10.23%)
IL-6 inhibitors
n=1424 (10.18%)
JAK inhibitors
n=713 (5.10%)
csDMARDs
n=3851 (27.52%)
Age, mean (SD), years55.1 (12.9)58.5 (12.8)58.2 (12.9)58.1 (11.8)57.1 (12.7)59.5 (11.9)58.9 (12.6)
Women, n (%)2439 (75.2)1801 (71.7)607 (74.3)1102 (77.0)1101 (77.3)531 (74.5)2837 (73.7)
RF positive, n (%)2188 (69.0)1664 (67.9)599 (75.2)1199 (84.3)996 (74.0)497 (71.2)2173 (57.3)
ACPA positive, n (%)1854 (68.6)1486 (67.8)482 (70.2)679 (76.0)844 (72.6)468 (68.6)1818 (54.5)
FFbH score, mean (SD)67.7 (22.2)65.9 (22.9)59.5 (23.5)56.0 (23.4)63.3 (23.7)63.4 (24.2)71.3 (21.9)
Disease duration, median (IQR), years7.0 (3.0–13.0)7.0 (3.0–13.0)10.0 (4.0–17.0)12.0 (7.0–19.0)9.0 (4.0–16.0)8.0 (3.0–16.0)3.0 (1.0–8.0)
DAS28, mean (SD)4.8 (1.3)4.9 (1.2)5.2 (1.3)5.3 (1.3)5.1 (1.3)4.7 (1.3)4.4 (1.3)
CRP, median (IQR), mg/L6.8 (2.9–15.9)7.3 (3.0–18.0)7.2 (3.0–19.3)9.1 (3.3–22.9)7.4 (2.6–20.0)6.1 (2.3–14.1)5.4 (2.3–12.8)
CDAI, median (IQR)22.0 (16.0–31.0)24.0 (17.0–32.0)25.0 (18.0–34.0)24.0 (15.0–34.0)24.0 (17.0–31.0)23.0 (16.0–31.0)18.0 (12.0–26.0)
Previous csDMARD therapies, mean (SD)2.2 (1.0)2.2 (1.0)2.5 (1.3)2.7 (1.3)2.3 (1.1)2.0 (0.9)1.3 (0.6)
Previous bDMARD/tsDMARD therapies, mean (SD)0.3 (0.7)0.2 (0.5)1.3 (1.3)1.7 (1.1)1.1 (1.2)1.0 (1.5)0.0 (0.2)
Methotrexate, n (%)1906 (58.8)1277 (50.8)556 (68.1)804 (56.2)513 (36.0)263 (36.9)2405 (62.5)
Glucocorticoids, n (%)1934 (59.7)1476 (58.8)463 (56.8)961 (68.0)822 (57.8)312 (43.9)1823 (47.4)
Glucocorticoids, ≥10 mg, n (%)490 (15.2)377 (15.0)128 (15.7)332 (23.6)269 (18.9)64 (9.1)291 (7.6)
Comorbidities, mean (SD)2.1 (2.2)2.5 (2.3)3.1 (2.7)2.8 (2.4)2.4 (2.3)2.8 (2.3)1.9 (2.0)
Osteoporosis, n (%)412 (12.7)450 (17.9)202 (24.7)402 (28.1)251 (17.6)123 (17.3)434 (11.3)
Hypertension, n (%)1214 (37.4)1124 (44.7)398 (48.7)600 (41.9)590 (41.4)340 (47.7)1673 (43.4)
Coronary heart disease, n (%)182 (5.6)193 (7.7)69 (8.4)111 (7.8)101 (7.1)60 (8.4)223 (5.8)
Diabetes, n (%)349 (10.8)312 (12.4)102 (12.5)161 (11.3)175 (12.3)96 (13.5)429 (11.1)
Chronic obstructive respiratory disease, n (%)119 (3.7)145 (5.8)59 (7.2)83 (5.8)64 (4.5)41 (5.8)173 (4.5)
Chronic kidney disease, n (%)146 (4.5)170 (6.8)53 (6.5)87 (6.1)75 (5.3)55 (7.7)147 (3.8)
Malignant neoplasia, n (%)90 (2.8)95 (3.8)36 (4.4)142 (9.9)48 (3.4)26 (3.6)157 (4.1)
Lymphoma/leukaemia, n (%)3 (0.1)4 (0.2)3 (0.4)39 (2.7)5 (0.4)3 (0.4)20 (0.5)
Mental illness/depression, n (%)246 (7.6)199 (7.9)70 (8.6)85 (5.9)127 (8.9)84 (11.8)250 (6.5)
  • ACPA, anticitrullinated protein antibodies; bDMARDs, biologic DMARDs; CDAI, Clinical Disease Activity Index; CRP, C reactive protein; csDMARDs, conventional synthetic DMARDs; DAS28, Disease Activity Score of 28 joints using the erythrocyte sedimentation rate; DMARDs, disease-modifying antirheumatic drugs; FFbH, Hannover Functional Status Questionnaire; IL-6, interleukin 6; JAK, Janus kinase; RF, rheumatoid factor; TNF, tumour necrosis factor; tsDMARDs, targeted synthetic DMARDs.